Tags : Nash

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

Shots: Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the approved product Merck to receive an exclusive license to develop, manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea Efinopegdutide […]Read More

Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH

Shots: Pliant to receive $80M including upfront & equity investment and eligible to receive development, regulatory and commercial milestones with royalties on sales. Novartis to get exclusive WW license for Pliant’s PLN-1474 and up to three additional candidates Novartis will be responsible for all future development, manufacturing and commercial activities, a post-P-I study of PLN-1474, […]Read More

Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study

Shots: The P-III STELLAR 3 study involves assessing of Selonsertib (18mg, 6mg) vs PBO in 802 patients with F3/bridging fibrosis due to NASH in adults aged 18 to 70yrs for 240wks. The P-III study results: @48 wks. did not meet its 1EPs; ≥ 1-stage improvement in fibrosis without NASH worsening (9.3%, 12.1% vs 13.2%); well […]Read More

Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy

Shots: Gilead collaborates with Novo for the onset of a clinical trial combining its Firsocostat and Cilofexor with Novo’s Semaglutide for the treatment of patients with Nonalcoholic Steatohepatitis (NASH) The focus of the collaboration is to combine Gilead and Novo’s expertise for the enhancement of research capabilities and approaches developing novel therapies in NASH Semaglutide […]Read More

Merck Exercises its Option to License NGM’s NGM313 (MK-3655) for

Shots:  NGM to receive $20M as total deal value with anoption to participate in P-III trial of MK-3655 with equal cost and revenue sharing. Merck to get exclusive worldwide rights to develop and commercialize NGM’s NGM313 (currently MK-3655) If the option is not exercised by NGM, it will receive milestones and royalties on sales of […]Read More

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Shots: Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis NLRP3 – Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3, investigated for the treatment of autoimmune and […]Read More